In recent years, the Chinese pharmaceutical market has seen strong demand and sustained high growth. At the same time, high-end manufacturing in China is also shifting from domestic substitution to global supply. Jingtai Capital is optimistic about the sustainable development prospects of the health and pharmaceutical industry and high-end manufacturing industry. In February 2024, Jingtai Capital invested in the Future Industry Equity Investment Fund (hereinafter referred to as the "Fund") established by Shoujian Investment, with Guangzhou Libai Group as the main investor. The fund mainly focuses on entrepreneurial investment in the health and pharmaceutical industry and high-end manufacturing industry. Currently, it has completed actual payment and filing, and the fund's investment business has gradually begun.

Shoujian Investment is a specialized alternative asset management institution that focuses on equity investment, a financial investment provider that promotes regional economic development and industrial transformation and upgrading, and an industry integrator. With strong resources and rich investment management experience, the invested industries involve high-end equipment manufacturing, cloud computing, intelligent hardware, and artificial intelligence.

This time, the investment cooperation between Jingtai Capital and Shoujian Investment aims to leverage the investment, empowerment, and integration capabilities of both sides in different industrial directions, forming a strategic complementary trend. In the Spring Festival season, inject new vitality and bring new momentum to the health and pharmaceutical industry and high-end manufacturing industry. Following the national strategy, providing capital support with more industrial elements for participating enterprises.